The company’s profit for Q1 2016, ended June 30, 2015, totaled $576 million, a 43 percent increase from the $403 million posted for the same time period last year.
Additionally, McKesson posted $47.5 billion in revenue for the quarter, up 9 percent from $43.5 billion a year ago.
According to a Wall Street Journal report, McKesson has benefited from the sale of two hepatitis C drugs, Gilead Sciences’ Sovaldi and Harvoni, which have been two of the most successful drug launches in history.
More articles on health IT:
Epic, Cerner, McKesson among highest IT revenue last year; athenahealth launches free messaging platform; Epic snags 2 new customers — 5 health IT key notes
How to create a culture of innovation: 6 lessons from Edward Marx
‘Think, build and run’: 4 IT leaders discuss the future of the industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.